1. Introduction

Endometrial cancer (EC) is the most common gynecologic malignancy, frequently presenting in early stages. For women with localized disease at diagnosis, 5-year survival rates exceed 90% (Siegel et al., 2014). For those with distant disease at diagnosis, 5-year survival is below 20% (Siegel et al., 2014). While early disease is often cured by primary surgery, adjuvant therapy is often administered for more advanced cases (Network NCC, 2014). According to the most recent National Comprehensive Cancer Network (NCCN) guidelines for EC, chemotherapy with or without the addition of radiation is considered to be the cornerstone of treatment for patients with surgically staged advanced disease. Certain risk features in women with early stage disease—advanced age, lymphovascular space invasion, large tumor size, lower uterine segment or surface cervical glandular involvement—may also receive adjuvant chemotherapy (Network NCC, 2014).

Chemoresistance remains an important factor in the management of EC. In GOG-177, a trial evaluating doxorubicin and cisplatin +/- paclitaxel in women with advanced or recurrent endometrial cancer, 25% of regimens were discontinued due to progressive disease (Fleming et al., 2004). Response durations in EC tend to be shorter than those for ovarian cancer (McMeekin et al., 2007). Over half of patients don’t respond to NCCN-recommended regimens at all (Network NCC, 2014; McMeekin et al., 2007) and may suffer from treatment-related toxicities without benefit. Ideally, chemotherapy would be used only in those likely to respond, while the predicted non-responders would receive other treatment modalities. With some data suggesting that genetic aggressiveness generally trends with grade, the objective of our study was to ascertain the association of tumor grade with chemotherapy response in patients with EEC.
2. Materials and methods

We conducted a multi-institutional IRB-approved retrospective study of EC at Duke University, the University of North Carolina-Chapel Hill (UNC) or the Medical University of South Carolina (MUSC). Inclusion criteria were advanced or recurrent EEC, documented tumor grade, treatment with chemotherapy between 1994 and 2013, and measurable disease using RECIST 1.1 criteria (RECIST, 2014). Patients must have received a minimum of 3 cycles of chemotherapy and have pre- and post-chemotherapy imaging available for review. Patients with recurrent disease were included for their response to salvage chemotherapy for measurable disease. Exclusion criteria were non-endometrioid histology, non-measurable disease, lack of assigned grade at diagnosis, synchronous primaries, or prior malignancy within 5 years of diagnosis. Pathology specimens were reviewed and tumor grades assigned at each respective institution. At UNC and MUSC there were 4 and 5 pathologists, respectively, who received pathology At Duke, the majority of specimens were reviewed by 3 senior pathologists at Duke. A single observer assessed RECIST responses retrospectively.

Statistical comparisons were performed using ANOVA tests for continuous variables, Chi-square tests were used to test associations of categorical variables. Due to the small number of subjects with grade 1 tumors, statistical analysis of tumor response among all grades was not conducted; grade 1 patients are presented with descriptive statistics only. Inferential statistical analyses were performed comparing grade 2 and grade 3 tumors. Our null hypothesis was that there is no difference in tumor response to chemotherapy based on tumor grade. Our experimental hypothesis was that tumor grade is associated with response; lower grade tumors exhibit lower response rates. Using the two-sample binomial arcsin approximation method (assuming a one-sided alpha of 0.05), we obtain 71% power to detect a 25% difference in response rates between grade 2 and grade 3 tumors. Statistical analyses were conducted using SAS v. 9.3 software (SAS Institute, Inc., Cary, NC).

3. Results

Ninety-one subjects met eligibility criteria: thirteen with grade 1, 29 with grade 2, and 49 with grade 3 tumors. Clinical characteristics are listed in Table 1. Most patients were Caucasian; neither age (mean 63) nor BMI (mean 33) differed substantially across tumor grade. Neoadjuvant chemotherapy was administered due to tumor burden in 5 patients (5.5%), as postoperative therapy for residual disease in 10 (11%), and for recurrence in 76 (84%) cases. All patients receiving neoadjuvant or postoperative chemotherapy received carboplatin and paclitaxel.

Table 2 summarizes objective responses stratified by most recently assigned grade. The overall response rate was 6/13 (46%) for grade 1, 21/29 (72%) for grade 2, and 21/49 (43%) for grade 3 tumors. Seventy percent of grade 2 tumors exhibited a response (CR or PR) compared to 43% of grade 3 tumors (p = 0.02). Seventy-seven patients received carboplatin/paclitaxel during the course of their treatment. Eighteen of 25 (72%) grade 2 tumors treated with this regimen achieved a response (CR or PR) compared to 17/41 (41%) of grade 3 tumors (p = 0.016).

Of the 15 patients receiving chemotherapy in the neoadjuvant or adjuvant setting, 6/6 (100%) grade 1/2 and 4/9 (44%) grade 3 tumors responded. Of the 48 patients treated for biopsy-proven progression or recurrence, 23 patients (48%) had a tumor grade re-assignment. Of these, 5 (22%) were upgraded compared to that assigned at diagnosis, while 78% retained their original grade. Among 37 patients with a recently assigned grade prior to starting chemotherapy (either in the neoadjuvant/post-operative setting or with a grade re-assigned at time of recurrence), 3 of 4 (75%) of grade 1 tumors achieved a response to treatment. Seven out of 8 patients (88%) with grade 2 tumors achieved a response compared to 11/25 (44%) of grade 3 tumors (p = 0.032). [Table 3].

| Table 1 | Patient characteristics by tumor grade on most recent biopsy. |
|---------|-----------------------------------------------------------|
|          | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Total n = 91 |
| Age at diagnosis, mean | 62.4 | 63.4 | 62.6 | 63.0 |
| Race/ethnicity | | | | |
| Caucasian/non-Hispanic | 10 (77) | 24 (83) | 32 (65) | 66 |
| Caucasian/Hispanic | 0 | 0 | 2 (4) | 2 |
| African-American | 1 (8) | 4 (14) | 14 (29) | 19 |
| Other | 2 (15) | 3 (1) | 1 (2) | 4 |
| BMI at diagnosis, mean | 29.6 | 33.9 | 33.5 | 33.1 |
| Chemotherapy setting | | | | |
| Neoadjuvant | 2 (15) | 0 | 3 (6) | 5 |
| Post-operative | 1 (7) | 3 (10) | 6 (12) | 10 |
| Recurrence | 10 (77) | 26 (90) | 40 (82) | 76 |
| Stage at presentation | | | | |
| I | 5 (38) | 18 (62) | 21 (43) | 44 |
| II | 0 | 2 (7) | 4 (8) | 6 |
| III | 2 (15) | 4 (14) | 13 (27) | 19 |
| IV | 6 (46) | 5 (17) | 11 (22) | 22 |
| Lymph nodes removed, mean (range) | | | | |
| Pelvic | 4 (0–12) | 14 (0–45) | 13 (0–53) | 12 |
| Para-aortic | 2 (0–7) | 3 (0–17) | 5 (0–29) | 4 |
| Recieved prior chemotherapy | 5 (38) | 4 (14) | 9 (18) | 20 |
| Target in prior irradiated field (n) | 2 | 8 | 9 | 19 |
| Chemotherapy regimen | | | | |
| Carboplatin/paclitaxel | 9 (68) | 25 (87) | 34 (69) | 68 (75) |
| Cisplatin/doxorubicin/paclitaxel | 1 (8) | 1 (3) | 2 (4) | 4 (4) |
| Cisplatin/pegylated liposomal doxorubicin | 1 (8) | 1 (3) | 1 (2) | 3 (3) |
| Gemcitabine/docetaxel | 1 (8) | 0 | 0 | 1 (1) |
| Other | 1 (8) | 2 (7) | 13 (25) | 16 (17) |
| BMI: Body mass index. | | | | |

| Table 2 | Response to chemotherapy based on most recent tumor grade. |
|---------|-----------------------------------------------------------|
|          | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) |
| Complete response | 3 (23) | 7 (24) | 6 (12) |
| Partial response | 3 (23) | 14 (48) | 15 (31) |
| Stable disease | 5 (39) | 7 (24) | 7 (14) |
| Progressive disease | 2 (15) | 1 (4) | 21 (43) |

The majority (10/13) of grade 1 tumors were treated for recurrent disease; two received neoadjuvant therapy, while one received post-operative chemotherapy. Both grade 1 subjects receiving neoadjuvant chemotherapy achieved a CR. The first was a patient with para-aortic lymphadenopathy, who received 4 cycles of neoadjuvant chemotherapy, and achieved a CR on follow-up imaging. At time of surgery, the only site of disease was focal residual tumor within the uterus. The second patient had biopsy-proven liver metastases and received 8 cycles of neoadjuvant chemotheraphy with a CR on pre-operative imaging (Fig. 1). At the time of surgery, there was no gross residual disease and no residual intra-uterine tumor on final pathology. The one subject with a grade 1 tumor who received post-operative chemotherapy achieved a partial response. The remaining grade 1 responses were seen in the group of 10 receiving treatment at recurrence (1 CR, 2 PR). At last follow-up, 4/10 patients had died of disease, 1 was without evidence of disease, 4
were alive with disease, and the remaining patient died of co-morbid conditions during treatment. Nineteen patients had measurable disease in fields of prior irradiation, 2 in the adjuvant setting and 17 with recurrence. Both tumors receiving radiation in the adjuvant setting had grade 3 cancers; one achieved a CR while the other progressed. Of the 17 tumors recurring in a previously irradiated field, neither of the two grade 1 tumors responded, while 4/8 (50%) grade 2 tumors and 1/7 (13%) grade 3 tumors did respond. All responses were PRs. One of the two grade 1 tumors, 0/8 grade 2 and 4/7 (57%) grade 3 tumors in prior irradiated fields progressed through chemotherapy.

4. Discussion

Given the significant chemo-resistance seen in EC (McMeekin et al., 2007), the ability to better predict which patients may benefit most from cytotoxic therapy would be of significant value. Our findings suggest that grade 2 endometrioid tumors may respond better to chemotherapy than grade 1 or 3 cancers. The use of RECIST criteria as an objective means of evaluating tumor response adds objectivity to our findings. Our study is unique in that we assessed disease response using original grade assigned at time of diagnosis, as well as the most recently assigned grade in the case of recurrent disease. Nearly 22% of patients with re-assigned grades at time of biopsy proven recurrence had upgrading of their tumors. The assessment of tumor grade at time of recurrence may be an important part of treatment planning for these patients. Surprisingly, there was no difference in obesity rates between tumor grades. This may be because the more aggressive, measurable grade 1 tumors that required chemotherapy were also less likely to fit the established BMI-cancer associations.

A prior retrospective study in EC was consistent with our findings; Bakkum-Gamez et al. found that adjuvant chemotherapy for stage IIIC EC improves extra-pelvic 5 year disease free survival (DFS) for patients with grade 1/2 EC but not grade 3 disease (93% vs. 54%, log-rank p = 0.02) (Bakkum-Gamez et al., 2014). Unlike our study, only 38% of grade 3 tumors were endometrioid, compared to 100% of grade 1/2 tumors (Bakkum-Gamez et al., 2014). In our study, grade 2 tumors responded more robustly than their grade 3 counterparts in both the overall cohort and the smaller cohort with recent biopsies. McMeekin et al. examined the relationship between histology and chemotherapy response in 4 GOG trials, finding that histology was not a significant independent predictor of response to chemotherapy, but was predictive of PFS and overall survival (McMeekin et al., 2007).

In EC, differential expression of molecular markers may correlate with heterogeneity between histologic grades: in one study, 84% of grade 1 and 0% of grade 3 tumors expressed PTEN (Daniilidou et al., 2013). Results from analyses of The Cancer Genome Atlas (TCGA) have identified molecular fingerprints that may account for clinical heterogeneity in endometrioid EC (EEC). Nearly 25% of grade 3, but only 5% of Grade 1 and 2 EECs, may have genetic signatures more closely related to aggressive serous endometrial carcinomas than their EEC counterparts (Cancer Genome Atlas Research N et al., 2013).

Nearly 25% of grade 3 EECs compared to only 5% of grade 1 and 2 may have genetic signatures more closely related to serous endometrial carcinomas than their EEC counterparts (Cancer Genome Atlas Research N et al., 2013). These findings suggest that, for a subgroup of EECs, genetic signatures may not correlate with traditional tumor grade or histology (Cancer Genome Atlas Research N et al., 2013). There may be more heterogeneity within tumor grade in EEC than previously thought. This observation warrants further investigation, as it may be important when counseling patients regarding treatment options.

A key limitation of our study is the lack of grade reassessment at recurrence in most cases. Of those receiving chemotherapy for biopsy-proven progression or recurrence, only 23 (48%) had a grade reassigned. Using only the recently biopsied tumors with assigned grades did not change the finding that grade 2 tumors were the most likely to respond to chemotherapy. In a previous study, Vandenput et al. demonstrated changes in tumor biology and hormone receptor expression at recurrence when compared to primary EC specimens. Lack of estrogen receptor expression (p < 0.05) and presence of p53 (p = 0.001) correlated negatively with survival (Vandenput et al., 2011). This may be an important area of improvement to better assess the likelihood of response to treatment in EC.

The major strength of this study is that it uses RECIST 1.1, an objective method of assessing disease response, across patients from several institutions. However, our study is limited by several other factors. Only 13 grade 1 tumors are included, limiting the comparisons that can be made using this small cohort. Patients with measurable disease who were treated with various chemotherapy regimens in either the upfront or the recurrent setting were included, contributing to heterogeneity and possibly limiting the applicability of this study to specific clinical situations. Other limitations include the lack of central pathology review, lack of training data set and the wide range of date range of case collection.

In conclusion, our multicenter study suggests that lower histologic grade is not associated with a decreased response to chemotherapy in patients with EEC. In this series, grade 2 tumors were associated with a favorable response rate of 72%. Data suggests that variations in molecular markers, in addition to tumor grade, may
contribute to tumor behavior. Larger series of prospectively accrued cases should be evaluated for correlations between tumor grade, gene expression profiles, and tumor response to test the associations identified in our study.

**Conflict of interest statement**

None of the authors have conflicts of interest to report.

**References**

Bakkum-Gamez, J.N., Mariani, A., Dowdy, S.C., Weaver, A.L., McGree, M.E., Martin, J.R., et al., 2014. Efficacy of contemporary chemotherapy in stage IIIIC endometrial cancer: a histologic dichotomy. Gynecol. Oncol. 132 (3), 578–584.

Cancer Genome Atlas Research N, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., et al., 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497 (7447), 67–73.

Daniilidou, K., Frangou-Plemenou, M., Grammatikakis, J., Grigoriou, O., Vitoratos, N., Kondi-Pafiti, A., 2013. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. J. BUON 18 (1), 195–201.

Fleming, G.F., Brunetto, V.L., Cella, D., Look, K.Y., Reid, G.C., Munkarah, A.R., et al., 2004. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 (11), 2159–2166.

McMeekin, D.S., Filaci, V.L., Thigpen, J.T., Gallion, H.H., Fleming, G.F., Rodgers, W.H., et al., 2007. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 (1), 16–22.

Network NCC, 2014. Uterine Neoplasms (1.2014).

RECIST, 2014. (cited June 2]. 1.1:[Available from:) http://www.recist.com/recist-in-practice/01.html.

Siegel, R., Ma, J., Zou, Z., Jemal, A., 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64 (1), 9–29.

Vandenput, I., Trovik, J., Leunen, K., Wik, E., Stefansson, I., Akslen, L., et al., 2011. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int. J. Gynecol. Cancer 21 (2), 316–322.